Drug Trial Radar · NCT00368537
Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
550
Actual
Start
Sep 2006
Primary completion
Sep 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 24, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).
Conditions
- Skin Diseases, Bacterial
Interventions
TigecyclineDrug
Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
ampicillin-sulbactamDrug
Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs. A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-cure (TOC) VisitTime frame: up to 6 weeks
Locations
57 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Scottsdale, Arizona
Site not named
Jonesboro, Arkansas
Site not named
Chula Vista, California
Site not named
Mission Viejo, California
Site not named
National City, California
Site not named
Denver, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Washington D.C., District of Columbia
Site not named
Orlando, Florida
Site not named
Vero Beach, Florida
Site not named
Fort Gordon, Georgia
Site not named
Idaho Falls, Idaho
Site not named
Decatur, Illinois
Site not named
Naperville, Illinois
Site not named
Springfield, Illinois
Site not named
Topeka, Kansas
Site not named
Cambridge, Massachusetts
Site not named
Worcester, Massachusetts
Site not named
Detroit, Michigan
Site not named
Lincoln, Nebraska
Site not named
Hackensack, New Jersey
Site not named
Neptune City, New Jersey
Site not named
Buffalo, New York
Site not named
Elmira, New York
Site not named
New Hyde Park, New York
Site not named
Columbus, Ohio
Site not named
Lima, Ohio
Site not named
Lansdale, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Fort Worth, Texas
Site not named
Houston, Texas
Site not named
Québec, Canada
Site not named
Winnipeg, Manitoba, Canada
Site not named
Chicoutimi, Quebec, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Sherbrooke, Quebec, Canada
Site not named
Trois-Rivières, Quebec, Canada
Site not named
Saskatoon, Saskatchewan, Canada
Site not named
Hong Kong, Hong Kong
Site not named
Ramat Gan, Israel
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.